CFTAX Fees and Costs — American Funds College 2024 Fund, Class 529-A
Data updated: 2024-03-28
The net expense ratio is 0.69%. This share class carries a maximum front-end sales load of 3.50% and a deferred sales charge of up to 1.00%. Portfolio turnover was 1%.
CFTAX Fees and Expenses
Annual operating expenses and sales charges of CFTAX. Prospectus, as of November 30, 2023.
| Annual operating expenses | |
|---|---|
| Management fee | 0.00% |
| 12b-1 fee | 0.24% |
| Other expenses | 0.18% |
| Gross expense ratio | 0.69% |
| Fee waiver | — |
| Net expense ratio | 0.69% |
| Sales charges | |
|---|---|
| Max front load | 3.50% |
| Max deferred load | 1.00% |
| Redemption fee | 0.00% |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
CFTAX Costs Over Time
On $10,000 invested in CFTAX, assuming 5% a year before costs, total costs come to $866 over 5 years, cutting the return by 1.46% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $451 | $350 | $350 |
| Fund expenses (net expense ratio 0.69%) | $70 | $219 | $381 |
| Lost growth on money paid in costs | $17 | $66 | $135 |
| Total costs | $538 | $635 | $866 |
| Value after costs | $9,962 | $10,941 | $11,897 |
| Impact on return, per year | 5.38% | 1.96% | 1.46% |
CFTAX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2023.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 1%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.